Oncimmune Holdings PLC GRANT OF OPTIONS (3496F)
17 May 2017 - 4:00PM
UK Regulatory
TIDMONC
RNS Number : 3496F
Oncimmune Holdings PLC
17 May 2017
Oncimmune Holdings PLC
17 May 2017
("Oncimmune" or the "Company")
GRANT OF OPTIONS
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) platform technology, announces that on 16 May 2017,
options over 13,339 ordinary shares of 1 pence each in the capital
of the Company ("Ordinary Shares") were awarded to a member of UK
staff under the Oncimmune Holdings Plc 2016 Unapproved & EMI
Share Option Plan. The options are subject to the rules of the
Oncimmune Holdings Plc 2016 Unapproved & EMI Share Option Plan
and vest in five equal annual parts, the first fifth vesting on 8
January 2018 and each year thereafter for a further four years,
subject to continued employment. The options are exercisable at
147.50 pence, being the mid-market closing price of the Ordinary
Shares on 15 May 2017.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey
Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBIGDUUDBBGRL
(END) Dow Jones Newswires
May 17, 2017 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024
